[Translation] Phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of RMX1001 in healthy Chinese adult subjects

主要目的：评估RMX1001在健康中国成年受试者中单次和多次给药剂量递增的安全性、耐受性次要目的： 1)确定人血浆中的主要代谢产物; 2)评估健康中国成年受试者单次和多次口服不同剂量RMX1001后RMX1001及其主要代谢产物的药代动力学特征；

[Translation]

Primary objective: To evaluate the safety and tolerability of single and multiple escalating doses of RMX1001 in healthy Chinese adult subjects Secondary objectives: 1) To determine the major metabolites in human plasma; 2) To evaluate the pharmacokinetic characteristics of RMX1001 and its major metabolites after single and multiple oral administration of different doses of RMX1001 in healthy Chinese adult subjects;

Start Date22 Oct 2019

Sponsor / Collaborator

Hangzhou Ruomaixing Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with RQ-00317076

100 Translational Medicine associated with RQ-00317076

100 Patents (Medical) associated with RQ-00317076

News (Medical) associated with RQ-00317076

11 Jun 2024

·askat-inc.com

Intellectual Property India Grants AskAt a Patent for AAT-076 Production Process

AskAt received a Letters Patent dated May 28, 2024 for a process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids (Patent Number: 539578). The Notice was issued by the Office of the Controller General of Patents, Designs & Trade Marks (CGPDTM) in connection with Indian Patent Application No. 202127037497 (Filing Date: January 20, 2020). To date, in addition to India, the process patent has also been granted in Brazil, Canada, China, Europe, Japan, Korea, Mexico, Russia, and the U.S. __PRESENT __PRESENT

Patent Expiration

17 Jan 2024

·askat-inc.com

Intellectual Property India Grants AskAt a Patent for AAT-076 Formulation

AskAt received a Letters Patent dated December 14, 2023 for a formulation patent for AAT-076, its COX-2 inhibitor. The Notice was issued by the Office of the Controller General of Patents, Designs & Trade Marks (CGPDTM） in connection with Indian Patent Application No. 641/MUMNP/2014 (Filing Date: October 18, 2012). To date, in addition to India, the formulation patent has been granted in Brazil, Canada, China, Europe, Japan, Korea, Mexico, Russia, and the U.S.

Patent Expiration

100 Deals associated with RQ-00317076

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain	Phase 2	-	RaQualia Pharma, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

RQ-00317076

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation